Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system, characterized by inflammation, demyelination, and neurodegeneration. Pregnancy often induces fluctuations in disease activity, with…
recently approved in the USA, Canada and Australia as an oral treatment for relapsing–remitting multiple sclerosis after positive results from two large pivotal Phase III studies. Approval is also ... considered to be…
symptoms of multiple sclerosis, but they are not considered to be true relapses of the disease. At least 50% of people with relapsing-relapsing multiple sclerosis eventually develop a steady ... experience a gradual…
Features of headache attacks during relapse and remission phases among patients with relapsing-remitting multiple sclerosis, (A) Types of headache, (B) severity of headache, (C) quality of headache, (D) location
type-1 diabetes patients and islet graft recipients, oligodendrocyte DNA in patients with relapsing multiple sclerosis, neuronal/glial DNA in patients after traumatic brain injury or cardiac arrest, and exocrine
Multiple sclerosis (MS) is a chronic and debilitating disease affecting approximately 2.5 million people worldwide, and safe and effective treatment options are sorely lacking. While there are several currently approved…
Background: Early diagnosis of multiple sclerosis (MS) can lead to preventive treatment and a favorable prognosis. Cervical spinal cord matter that appears normal on conventional MR images may be detected ... pinpoint…
Background: Relapse-remitting multiple sclerosis is a chronic disorder that affects more than 400,000 individuals in the United States, often reducing their quality of life, increasing medical expenses ... dosages of…
Fingolimod (Gilenya®) is the first oral immunomodulating drug approved for relapsing–remitting multiple sclerosis. Its novel mechanism of action inhibits the egress of autoreactive B and T cells from lymph ... clinical…
variant of Multiple sclerosis, with recent advances in investigations and with better understanding of etiopathogenesis, NMO is a distinct immune mediated, largely relapsing, inflammatory, demyelinating disease of…
highly common. Herein we report a case of a manic episode following a multiple sclerosis relapse in a young male subject without past history of psychiatric illness. The patient
Interferon-beta is recognized as first line treatment in relapsing remitting multiple sclerosis. Overall it is considered a safe drug; however, over the years there has been some concern ... present a case of nephrotic…
state of the choroidal tract of the apple of the eye in patients with multiple sclerosis. As the new possibilities of the choroid visualization have emerged, the interest towards ... contains the results of retina and…
state of the choroidal tract of the apple of the eye in patients with multiple sclerosis. As the new possibilities of the choroid visualization have emerged, the interest towards ... contains the results of retina and…
kidney function restored. Interferon β1α resumed 16 weeks after stopping treatment due to multiple sclerosis relapse. On an iterative fundus exam 3 months after resumption of interferon β1α, no further
Fingolimod is a well known immunomodulator used by oral route in relapsing multiple sclerosis patients. Upon phosphorylation by sphingosine kinase 2 (SPHK2), fingolimod binds to one or more
relied on the use of self-injectable disease modifying agents for the treatment of multiple sclerosis. The need for frequent injections has affected treatment up take and adherence. Fingolimod ... comparison to placebo…
directly target glial cells. Fingolimod is a widely used treatment for highly active relapsing-remitting multiple sclerosis. Objective: Here we investigate effects of fingolimod on expression of whether pre-treatment…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.